In recent years, peptide as a therapeutic drug has attracted more and more attention. At present, nearly 60 peptide products have been approved for marketing in the world. Recently, the "Symposium on polypeptide drugs of advanced technology research institute of University of science and technology of China" hosted by the Institute of advanced research of University of science and technology of China and organized by the laboratory of protein and polypeptide drugs of the Institute of advanced research of University of science and technology of China was held in Hefei.

The development prospect of biomedical industry is good, and drug R & D is a key link in the industrial chain. Recently, the "Symposium on polypeptide drugs of advanced technology research institute of University of science and technology of China" hosted by the Institute of advanced research of University of science and technology of China and organized by the laboratory of protein and polypeptide drugs of the Institute of advanced research of University of science and technology of China was held in Hefei. The reporter learned that in the future, the Institute will focus on peptide drug research and development and industrialization, and actively promote internationally renowned pharmaceutical enterprises to develop the biomedical industry in Anhui and Hefei.

What is "polypeptide" and "polypeptide drug"? According to the introduction, polypeptide generally refers to a compound composed of less than 100 amino acids connected by peptide bond, and its relative molecular weight is less than 10000. Peptide drug is one of the most important innovative biological drugs. At present, most of the common western medicines on the market are small molecule chemicals. Compared with small molecule chemical drugs, peptide drugs are superior to small molecule chemical drugs in biological activity, specificity and solving complex diseases. Compared with protein drugs, peptide drugs have better stability, higher purity and lower cost. The quality control level of peptide drugs is close to that of small molecule chemicals, and the activity is close to that of protein drugs. It has the characteristics of high activity, low dose and low toxicity. Combining the advantages of the two, it is suitable for solving complex diseases that are difficult to be solved by small molecule chemicals. It is mainly aimed at the unmet medical needs such as infection, tumor and metabolic diseases, and widely used in endocrine system Immune system, digestive system, cardiovascular system, blood system, musculoskeletal system, etc. That is to say, with the development of medicine and biochemical technology, peptide drugs have become important drugs for diagnosis, monitoring, prevention and treatment.

The global market share of peptide drugs in 2015 was about 19.6 billion US dollars, maintaining a high growth rate of about 10%. Among them, the innovative peptide drug market is about US $10.2 billion. In China, 14 peptide preparations have been sold on the market, 4 of which are all imported, and 10 belong to generic drugs or dosage forms.

At present, the development of biopeptide drugs in Anhui Province is relatively backward, and it has not yet formed industrial driving role and industrial agglomeration, so it is necessary to further increase investment to attract high-level R & D talents and well-known enterprises. According to Tian Changlin, professor and doctoral director of School of life sciences, University of science and technology of China, and director of protein and polypeptide medicine laboratory, Institute of advanced technology, University of science and technology of China, the laboratory mainly develops polypeptide drugs with important market significance for analgesia, immune diseases and other diseases, and actively helps Anhui Province to introduce internationally renowned pharmaceutical enterprises to develop regional biopharmaceutical industry.

It is worth noting that during the conference, a number of well-known pharmaceutical companies around the world expressed their intention to strengthen exchanges and R & D cooperation.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.